Recent market data shows that the healthcare sector in India is undergoing rapid transformation. Specifically, a major wave of hospital expansion in India is underway, driving robust top-line performance across listed chains. According to a new research report by Kotak Securities, major hospital players are sustaining double-digit revenue growth. However, aggressive bed-addition cycles are keeping operational margins rangebound as companies digest new capital investments.

How Hospital Expansion in India Affects Margins

To understand this financial dynamic, we must look at the recent March quarter results. During this period, Indian hospitals achieved an impressive 18 percent year-on-year (YoY) sales growth. Furthermore, cumulative EBITDA grew by 16 percent YoY, reflecting robust market demand. Importantly, healthy Average Revenue Per Occupied Bed (ARPOB) growth of 6 to 14 percent drove this positive momentum. Consequently, a reduced Average Length of Stay (ALOS) and an optimized specialty mix helped boost overall realizations. Specifically, KIMS registered a 14 percent YoY ARPOB growth due to strong contributions from Bengaluru and Thane.

Operational Nuances and Startup Losses

Meanwhile, other major hospital chains showed varying operational trends. For instance, Medanta saw a 6 percent YoY ARPOB rise despite launch costs from its new Noida facility. Similarly, Apollo Hospitals experienced a 9 percent YoY Average Revenue Per Patient (ARPP) growth. Additionally, they recorded a 7 percent volume increase in inpatient footfalls. In contrast, Max Healthcare emerged as an outlier with only 1 percent YoY ARPOB growth. This stagnation occurred because Max discontinued high-value chemotherapy drugs for CGHS patients and faced GST rate cuts. Consequently, oncology's share of sales at Max dropped to 21 percent from 26 percent. Nevertheless, excluding oncology, Max's gross revenues still expanded by 15 percent YoY.

Capacity Expansion and Diagnostic Performance

Despite short-term margin pressures, capacity building remains a key priority for most healthcare providers. Indeed, almost all coverage hospitals raised their operational bed counts by 5 to 21 percent YoY. For example, Apollo Hospitals saw its capacity beds jump by 6 percent quarter-on-quarter. However, this aggressive expansion naturally led to startup losses, particularly in new units. Specifically, losses from four of Apollo's new hospitals reached Rs 414 million in the fourth quarter. Meanwhile, established mature units continued to perform well, maintaining a solid EBITDA margin of 25.5 percent.

Strong Traction in Diagnostic Services

Furthermore, alongside clinical expansion, diagnostic players reported stellar performance. For instance, Dr. Lal PathLabs and Metropolis achieved 15 to 17 percent YoY organic sales growth. Specifically, sample volumes grew by 9 to 13 percent alongside an expanding wellness mix. Additionally, business-to-consumer (B2C) traction improved as online aggregators reduced their heavy discounts. Moreover, Metropolis boosted its sales growth to 23 percent YoY through key acquisitions like Ambika. Consequently, cumulative diagnostic EBITDA grew by 27 percent YoY, which highlights excellent operating leverage.

Frequently Asked Questions

Q1: Why are EBITDA margins of Indian hospitals staying rangebound despite high revenue growth?

Indian hospitals are aggressively adding new beds and opening new facilities. While mature units remain highly profitable, startup losses and launch expenses from these new units temporarily offset overall margins, keeping them rangebound.

Q2: What operational factors helped drive ARPOB growth for hospital players?

Average Revenue Per Occupied Bed (ARPOB) growth was primarily driven by a shorter Average Length of Stay (ALOS) and an improved, higher-value specialty mix across established centers.

Q3: How did diagnostic providers perform during this quarter?

Diagnostic companies performed exceptionally well, showing 15 to 17 percent organic revenue growth. This was supported by increased sample volumes, a larger wellness mix, and reduced discounting by online competitors.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Hospital expansion cycle to keep margins rangebound, but 18% revenue growthtrend likely to sustain: Kotak Securities - ETHealthworld


2. Why Indian Hospital Stocks Are Quiet Market Winners - Kotak Neo


3. Indian Hospital Industry - ICRA